Friday, June 08, 2018 5:40:51 PM
Address Congressional Subcommittee
DURHAM, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C.
The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.
“Unfortunately, the threat of a biological event impacting the United States has never been more real,” said Dr. Berrey. “Our private-public partnerships over the last 15 years, particularly with BARDA, have been critical to the survival and progression of our smallpox program with brincidofovir. We commend the Committee for bipartisan collaboration on the PAHPA reauthorization. Companies like ours rely on the existence of a government market for medical countermeasures to sustain the long-term investment of researching and developing these therapies, which provide a critical bulwark against biological threats.”……………...
Recent CMRX News
- Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/30/2024 08:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/13/2024 08:05:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 11:22:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 11:03:39 AM
- Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 08/13/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 05:26:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 04:01:08 PM
- Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/05/2024 08:05:00 PM
- Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2024 04:15:24 AM
- Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- Chimerix Appoints Marc D. Kozin to Board of Directors • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/29/2024 02:20:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 01:24:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:58:26 PM
- Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Chimerix to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:02:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:01:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:00:36 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM